CSTEC Renewed a Research Grant from SCM Lifescience, Total 1.5 Million
In collaboration with SCM Lifescience (SCM-LS, South Korea), CSTEC renewed a research grant for the project “Development of Clonal BMSC Sheets for Kidney Fibrosis Treatment”. The new renewal amount of $500K puts the total research amount at $1.5M.
SCM-LS has developed GMP-grade, clinically approved, clonal Bone Marrow Stromal Cells (BMSCs) isolated by their patented subfractionation culture method (Patent No. US 7,781,211 B2). Use of clonal BMSCs generated from a single-cell derived colony enables the rational selection of therapeutically relevant BMSC populations to eliminate variability of the products and stabilize/enhance therapeutic effects for targeted diseases. The merger of “cell sheet” and “clonal BMSC” technologies should improve MSC product reliability and QA/QC controls as well as therapy from enhanced cell engraftment/retention and reduced product variability.
